Study identifier:D4280C00011
ClinicalTrials.gov identifier:NCT01430910
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase I, 2-Part, Open-Label, Pharmacokinetic and Drug-Drug Interaction Study of CAZ104 (Avibactam and Ceftazidime in Healthy Subjects)
Healthy
Phase 1
Yes
CAZ104, Avibactam, Ceftazidime
All
43
Interventional
18 Years - 50 Years
Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Basic Science
Verified 01 Apr 2016 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: 1 CAZ104 (2000mg Ceftazidime/500mg Avibactam) | Drug: CAZ104 IV infusion |
Active Comparator: 2 500mg Avibactam | Drug: Avibactam IV infusion |
Active Comparator: 3 2000mg Ceftazidime | Drug: Ceftazidime IV infusion |